PARP1 and neoplasm: A breast cancer study by Hu et al. (2019) demonstrated that the PARP1 inhibitor Olaparib significantly enhanced chemotherapeutic agent (cisplatin and doxorubicin) sensitivity by reducing tumour suppressor BRD7 degradation caused by PARP1 overexpression in resistant cancer cells [75].